{"id":25325,"date":"2026-09-24T12:50:38","date_gmt":"2026-09-24T08:50:38","guid":{"rendered":"https:\/\/medscriptum.org\/?p=25325"},"modified":"2026-09-24T12:53:29","modified_gmt":"2026-09-24T08:53:29","slug":"myth-or-reality-10-facts-about-modern-smart-cancer-drugs","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/myth-or-reality-10-facts-about-modern-smart-cancer-drugs\/","title":{"rendered":"Myth or Reality? 10 Facts About Modern “Smart” Cancer Drugs"},"content":{"rendered":"

“Smart drug.” We hear this term almost every day in clinic, from patients who found it online, from colleagues outside oncology, sometimes even in the hallway before tumor board. People imagine a pill or infusion that hunts down cancer cells with remarkable accuracy and leaves everything else untouched. So where does the name actually come from, and how much of what we hear about it is actually true?<\/span><\/p>\n

“Smart” cancer drugs really cover two different drug categories. The first one is <\/span>targeted therapy<\/b>, which blocks a specific molecule the tumor depends on to grow (e.g. a mutated protein or receptor). The second one is <\/span>immunotherapy<\/b>, which doesn’t attack the tumor directly at all; it releases the brakes on the patient’s own immune system so it can recognize and fight cancer cells itself. Both are more precise than traditional chemotherapy, which affects any fast-dividing cell in the body regardless of whether it’s cancerous. That precision is real, but “smart” doesn’t mean simple, harmless, or guaranteed to work.<\/span><\/p>\n

Here are 10 myths we hear about these drugs almost daily and the real facts behind each one:<\/span><\/p>\n

    \n
  1. “It works for any cancer.” <\/b>Myth.<\/b> These drugs only work if the tumor actually carries the matching target, a specific mutation, protein or biomarker such as EGFR, HER2, PD-L1, or microsatellite instability. Without that match, response rates fall sharply, no matter how advanced the drug is. That’s why biomarker testing before treatment is essential. It is what lets us choose the right treatment plan for each patient.<\/span><\/li>\n
  2. “Targeted means no side effects.” <\/b>Myth.<\/b> Targeted drugs have their own toxicity profiles, e.g. skin rash with BRAF inhibitors (dabrafenib, trametinib), diarrhea with EGFR inhibitors (osimertinib), hypertension and bleeding risk with anti-angiogenic agents (bevacizumab). The pattern differs from classic chemotherapy, but the toxicity is never absent.<\/span><\/li>\n
  3. “Immunotherapy is gentler since it just helps the immune system.” <\/b>Myth<\/b> – sometimes the opposite.<\/b> An activated immune system doesn’t always stay selective for the tumor; it can turn against healthy organs such as skin, gut, lungs, thyroid, or even the heart. Roughly a third of patients develop a clinically meaningful immune-related side effect, which is why monitoring continues throughout treatment, not only at the start.<\/span><\/li>\n
  4. “It’s a cure.” <\/b>Mostly myth<\/b>.<\/b> For most patients with advanced disease, these drugs control cancer as a long-term, manageable condition rather than eliminate it. Still, some patients, particularly some melanoma and lung cancer patients on immunotherapy or target therapy, do reach durable remission, which is part of why the hope around these drugs is real.<\/span><\/li>\n
  5. “One genetic test at diagnosis is enough.” <\/b>Myth.<\/b> Tumors are moving targets: under treatment pressure, cancer cells often develop new resistance mutations over time. When a targeted therapy stops working, repeat testing, sometimes a simple blood-based liquid biopsy, frequently reveals a new, treatable target rather than a dead end.<\/span><\/li>\n
  6. “This is brand-new and experimental.” <\/b>Myth.<\/b> Targeted therapy has over two decades of clinical history. Imatinib’s 2001 approval for chronic myeloid leukemia is often called the breakthrough that proved precision oncology worked.<\/span><\/li>\n
  7. “Immunotherapy works faster than chemo.” <\/b>Myth.<\/b> Because it acts through the immune system rather than killing cells directly, benefit can take longer to show on scans. Tumors can even appear to grow briefly before shrinking, a recognized pattern called \u201cpseudoprogression\u201d, which is why response criteria for immunotherapy differ from those used for chemotherapy.<\/span><\/li>\n
  8. “Combining both is always better.” <\/b>Myth.<\/b> Combination strategies generally help in specific settings, but combining mechanisms also tends to combine or amplify their side effects. More drugs isn’t automatically more effective; the right combination depends on cancer type and biomarker profile.<\/span><\/li>\n
  9. “These drugs replace chemo and surgery.” <\/b>Myth.<\/b> In most treatment plans, targeted therapy and immunotherapy are added alongside surgery, radiation, and conventional chemotherapy, not used instead of them. Multidisciplinary, multimodal treatment is still what drives outcomes for most solid tumors.<\/span><\/li>\n
  10. “If it stops working, there’s nothing left to try.” <\/b>Myth.<\/b> Progression on one drug rarely means the end of options. Re-biopsy or liquid biopsy can uncover a new actionable mutation, and newer-generation agents are specifically designed to overcome known resistance pathways, switching drug class is a standard, switching drug class is a normal step in treatment planning, not a last resort.<\/span><\/li>\n<\/ol>\n

    “Smart” cancer drugs have genuinely reshaped oncology. But knowing what they can and can’t do, for the doctors prescribing them and the patients taking them, is what turns that promise into real, informed decisions. In countries with limited drug reimbursement, like Georgia, where most of these drugs are still not reimbursed, getting the facts right matters even more because patients aren’t just deciding on treatment, they’re deciding what to spend their savings on.<\/span><\/p>\n

    Author: Ana Geguchadze, MD, Medical Oncologist, Clinical Research Coordinator, Visiting Lecturer in Medical Genetics \u2014 Caucasus Medical Centre, European University<\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

    “Smart drug.” We hear this term almost every day in clinic, from patients who found it online, from colleagues outside oncology, sometimes even in the hallway before tumor board. People imagine a pill or infusion that hunts down cancer cells with remarkable accuracy and leaves everything else untouched. So where does the name actually come […]<\/p>\n","protected":false},"author":12,"featured_media":20018,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5963],"tags":[7157,7156,7158],"class_list":["post-25325","post","type-post","status-publish","format-standard","has-post-thumbnail","category-oncofeed-en","tag-smart-cancer-drugs","tag-medical-oncologist","tag-ana-geguchadze"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=25325"}],"version-history":[{"count":2,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25325\/revisions"}],"predecessor-version":[{"id":25328,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25325\/revisions\/25328"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/20018"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=25325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=25325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=25325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}